Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

  Exhibit 4.23    
    

FORM
OF UNIT PUT WARRANT 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE
SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO PROUROCARE
MEDICAL INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

 WARRANT TO PURCHASE

COMMON STOCK

OF

PROUROCARE MEDICAL INC.  

 VOID AFTER DECEMBER 31, 2012  

        This Warrant is issued to                         , or its registered assigns
("Holder") by ProUroCare Medical Inc., a Nevada corporation (the
"Company"), on [                        , 20    ](1) (the
"Warrant Issue Date")
for a purchase price of $[            ] (the "Warrant Purchase Price"). This Warrant is issued pursuant to the terms of that
certain Unit Put Agreement dated as of
[                                    ], 2008 (the "Put Agreement") in connection with the Company's issuance
to the Holder of a Convertible Promissory Note dated as of the date hereof (the "Note"), in the original principal amount of
$                                    . This
Warrant is intended to be an investment warrant and is not issued in consideration of any services. 

        1.    Purchase of Shares.    Subject to the terms and conditions hereinafter set forth and set forth in the Put
Agreement, the Holder is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the holder hereof in writing), to purchase
from the Company up to [                                    ](2) fully
paid and nonassessable shares of Common Stock of the Company, as constituted on the Warrant Issue Date (the
"Common Stock"). The number of shares of Common Stock issuable pursuant to this Section 1 (the
"Shares") shall be subject to adjustment pursuant to Section 8 hereof. 

        2.    Exercise Price.    The purchase price for the Shares shall be $1.00 per share (the "Exercise Price"). 

        3.    Exercise Period.    This Warrant shall be immediately exercisable, in whole or in part, and it shall remain so
exercisable until 5:00 p.m., Minneapolis time, on December 31, 2012. For purposes of this Warrant, "Public Offering" shall mean an
underwritten public offering of equity securities of the Company. 

        4.    Method of Exercise.    While this Warrant remains outstanding and exercisable in accordance with
Section 3 above, the Holder may exercise, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by: 

        (a)   the
surrender of the Warrant, together with a duly executed copy of the form of Notice of Exercise attached hereto, to the Secretary of the Company at its principal
offices; 

        (b)   the
payment to the Company of a cash amount equal to the aggregate Exercise Price for the number of Shares being purchased; and 

        (c)   the
delivery of a subscription agreement, an investment letter or similar document acceptable to the Company demonstrating that the sale of Shares to be purchased is
exempt from registration under the
Securities Act of 1933, as amended (the "Securities Act"), and any applicable state securities laws (unless a registration statement covering the Shares
being purchased shall have been declared effective by the Securities and Exchange Commission (the "Commission")). 

	(1)
	The
date of the Closing at which this warrant is issued under the Unit Put Agreement.  
	(2)
	20,000
shares for every $100,000 of purchase commitment by the Holder under the Unit Put Agreement. 

        5.    Certificates for Common Stock.    Upon the exercise of the purchase rights evidenced by this Warrant, one or
more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, bearing the restrictive legend set forth in Section 12 of this Warrant, and in any
event within 30 days of the delivery of the subscription notice. 

        6.    Intentionally Omitted.    

        7.    Issuance of Shares.    The Company covenants that the Shares, when issued pursuant to the exercise of this
Warrant, will be duly and validly issued, fully paid and nonassessable and free from all taxes, liens, and charges with respect to the issuance thereof. 

        8.    Adjustment of Exercise Price and Number of Shares.    The number of and kind of securities purchasable upon
exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows: 

        (a)    Subdivisions, Combinations and Other Issuances.    If the Company shall at any time prior to the expiration of
this Warrant subdivide its Common Stock, by split-up or otherwise, or combine its Common Stock, or issue additional shares of its Common Stock as a dividend with respect to any shares of
its Common Stock, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately
decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares
purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 8(a) shall become effective at the close of business on the date the subdivision or
combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend. 

        (b)    Reclassification, Reorganization, Consolidation, Merger and Other Changes.    In case of any reclassification,
capital reorganization or change in the Common Stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 8(a) above), or
consolidation or merger of the Company with or into another corporation, or the sale of all or substantially all of its assets to another corporation shall be effected in such a way that holders of
the Company's Common Stock shall be entitled to receive stock, securities or assets with respect to or in exchange for such Common Stock, then, as a condition of such reclassification, reorganization,
change, consolidation, merger or sale, lawful provision shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the
Holder shall have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of
stock and other securities and property receivable in connection with such reclassification, reorganization, change, consolidation, merger or sale by a holder of the same number of shares of Common
Stock as were purchasable by the Holder immediately prior to such reclassification, reorganization, change, consolidation, merger or sale. In any such case appropriate provisions shall be made with
respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon
exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price shall remain the same. 

        (c)    Minimum Adjustment.    Notwithstanding anything herein to the contrary, no adjustment under this
Section 8 need be made to the Exercise Price unless such adjustment would require an increase or decrease of at least 1% of the Exercise Price then in effect. Any lesser adjustment shall be
carried forward and shall be made at the time of and together with the next subsequent adjustment, which, together with any adjustment or adjustments so carried forward, shall amount to an increase or
decrease of at least 1% of such Exercise Price. Any adjustment to the Exercise Price carried forward and not theretofore made shall be made immediately prior to the conversion of this Warrant pursuant
thereto. 

        (d)    Other Adjustment.    If the Company at any time or from time to time shall take any other action, or if any
other event occurs, affecting the shares of Common Stock or its other equity interests, if any, other than an action described in this Section 8, then, and in each such case, the Exercise Price
shall be adjusted in such manner and at such time as the Board of Directors of the Company in good faith determines to be equitable in the circumstances (such determination to be evidenced in a
resolution, a certified copy of which shall be mailed to the Holder). 

        (e)    Notice of Adjustment.    When any adjustment is required to be made in the number or kind of shares purchasable
upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of shares of Common Stock or other securities or property
thereafter purchasable upon exercise of this Warrant setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. 

        9.    No Fractional Shares or Scrip.    No fractional shares or scrip representing fractional shares shall be issued
upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefore on the basis of the Exercise Price then in effect. 

        10.    No Stockholder Rights.    Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of
a stockholder with respect to the Shares, including (without limitation) the right to vote such Shares, receive dividends or other distributions thereon, exercise preemptive rights or be notified of
stockholder meetings, and such holder shall not be entitled to any notice or other communication concerning the business or affairs of the Company. However, nothing in this Section 10 shall
limit the right of the Holder to be provided the Notices required under this Warrant or the Put Agreement. 

        11.    Exchange of Warrant.    This Warrant is exchangeable, without expense, at the option of the Holder, upon
presentation and surrender hereof to the Company for other Warrants of different denominations entitling the Holder thereof to purchase in the aggregate the same number of Warrant Shares purchasable
hereunder on the same terms and conditions as herein set forth. 

        12.    Application of Restrictions on Transfer.    

        (a)    Transferability.    No transfer of this Warrant may be completed unless and until (i) the Company has
received an opinion of counsel for the Company that such securities may be sold pursuant to an exemption from registration under the Securities Act, or (ii) a registration statement relating to
this warrant has been filed by the Company and declared effective by the Commission. Subject to the foregoing, this Warrant and all rights hereunder are transferable, in whole or in part, at the
principal office of the Company by the Holder in person or by duly authorized attorney, upon surrender of this Warrant properly endorsed to any person or entity who represents in writing that
he/she/it is acquiring the warrant for investment and without any view to the sale or other distribution thereof. Each Holder of this Warrant, by taking or holding the same, consents and agrees that
the bearer of this Warrant, when endorsed, may be treated by the Company and all other persons dealing with this warrant as the
absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Warrant or perform the obligations required hereby, or to the transfer hereof on the books
of the Company, any notice to the contrary notwithstanding; but until such transfer on such books, the Company may treat the registered owner hereof as the owner for all purposes. 

        (b)    Restrictive Legend.    Each certificate for shares issued upon the exercise of the rights represented by this
Warrant shall bear a legend as follows unless, in the opinion of counsel to the Company, such legend is not required in order to ensure compliance with the Securities Act: 

        "THE
SECURITIES EVIDENCED BY THIS CERTIFICATE WERE ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES
LAWS, AND IN RELIANCE UPON THE HOLDER'S REPRESENTATION THAT SUCH SECURITIES WERE BEING ACQUIRED FOR INVESTMENT AND NOT FOR RESALE. NO TRANSFER OF THE SECURITIES MAY BE MADE ON THE BOOKS OF THE COMPANY
UNLESS (i) SUCH TRANSFER IS MADE PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES 

ACT
OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS OR (ii) THE HOLDER SHALL HAVE PROVIDED THE COMPANY WITH AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO THE COMPANY TO THE
EFFECT THAT NO SUCH REGISTRATION IS REQUIRED." 

        13.    Successors and Assigns.    The terms and provisions of this Warrant and the Put Agreement shall inure to the
benefit of, and be binding upon, the Company and the Holders hereof and their respective successors and assigns. 

        14.    Loss or Mutilation of Warrant.    Upon receipt by the Company of evidence satisfactory to it of the loss,
theft, destruction, or mutilation of this Warrant, and (in the case of loss, theft or destruction) or reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if
mutilated, the Company will execute and deliver a new Warrant of like tenor and date and any such lost, stolen or destroyed Warrant shall thereupon become void. Any such new Warrant executed and
delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed, or mutilated shall be at any time enforceable by
anyone. 

        15.    Amendments and Waivers.    Any term of this Warrant may be amended and the observance of any term of this
Warrant may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holders of warrants representing a
majority of the shares then issuable pursuant to the exercise of Warrants issued pursuant to the Put Agreement (the "Majority Purchasers");  provided, however, that no amendment, change or modification respecting this Warrant may be made by the Majority Purchasers without the consent of the
Holder
unless a comparable amendment, change or modification is made respecting all of the Warrants issued pursuant to the Put Agreement. Any waiver or amendment effected in accordance with this
Section 15 shall be binding upon each holder of a Warrant purchased under the Put Agreement, each future holder of all such Warrants and the Company. 

        16.    Effect of Amendment or Waiver.    The Holder acknowledges that by operation of Section 15 hereof, the
holders of warrants representing a majority of the shares then issuable pursuant to the exercise of Warrants issued pursuant to the Put Agreement will have the right and power to diminish or eliminate
all rights of such holder under this Warrant or under the Put Agreement. 

        17.    Notices.    All notices required under this Warrant shall be deemed to have been given or made for all purposes
(i) upon personal delivery, (ii) upon confirmation receipt that the communication was successfully sent to the applicable number if sent by facsimile; (iii) one day after being
sent, when sent by professional overnight courier service, or (iv) five days after posting when sent by registered or certified mail. Notices to the Company shall be sent to ProUroCare
Medical Inc., 5500 Wayzata Blvd., Suite 310, Golden Valley, MN, 55416 (or at such other place as the Company shall notify the Holder hereof in writing). Notices to the Holder shall be
sent to the address of the Holder on the books of the Company (or at such other place as the Holder shall notify the Company hereof in writing). 

        18.    Attorneys' Fees.    If any action of law or equity is necessary to enforce or interpret the terms of this
Warrant, the prevailing party shall be entitled to its reasonable attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. 

        19.    Captions.    The section and subsection headings of this Warrant are inserted for convenience only and shall
not constitute a part of this Warrant in construing or interpreting any provision hereof. 

        20.    Governing Law.    This Warrant shall be governed by the laws of the State of Minnesota as applied to agreements
among Minnesota residents made and to be performed entirely within the State of Minnesota. 

        IN WITNESS WHEREOF, ProUroCare Medical Inc. caused this Warrant to be executed by an officer thereunto duly authorized. 

					
	 	 	PROUROCARE MEDICAL INC.
	

 	
 	

By:	
 	

 
	 	 	 	 	

 
	 	 	Name:	 	 
	 	 	 	 	

 
	 	 	Title:	 	 
	 	 	 	 	

 

 WARRANT ASSIGNMENT  

 (to be signed only upon transfer of this warrant)  

        FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto                                    the right represented by the
within
Warrant to purchase, from ProUroCare Medical Inc., a Nevada corporation (the "Company"), shares of the Common Stock of the Company, to which the
within Warrant relates and
appoints                                    attorney to transfer said
right on the books of ProUroCare Medical Inc., with full power of substitution in the premises. 

					
	Dated:	 	 	 	 
	 	 	

 	 	 
	

 	
 	

 	
 	

Signature
	

 	
 	

Social Security or other Tax Identification No.
	

 	
 	

 
	

Please print present name and address	
 	

 
	

ATTEST:	
 	

 	
 	

 
	

Name:	
 	

 

 NOTICE OF EXERCISE  

To:
ProUroCare Medical Inc. 

        The
undersigned hereby elects to
purchase                                    shares of Common Stock of
ProUroCare Medical Inc., pursuant to the terms of the attached Warrant and payment of the
Exercise Price per share required under such Warrant accompanies this notice. 

        The
undersigned hereby represents and warrants that the undersigned is acquiring such shares for its own account for investment purposes only, and not for resale or with a view to
distribution of such shares or any part thereof. 

					
	 	 	Name of Warrant Holder
	

 	
 	

By:	
 	

 
	 	 	 	 	

 
	 	 	Name:	 	 
	 	 	 	 	

 
	 	 	Title:	 	 
	 	 	 	 	

 
	

 	
 	

Address:
	

 	
 	

 
	

 	
 	

 
	

 	
 	

 

 

					
	Date:	 	 	 	 
	 	 	

 	 	 
	

Name in which shares should be registered:	
 	

 
	

 	
 	

 

QuickLinks

Exhibit 4.23QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

  Exhibit 10.43    
    

 
 

  PROUROCARE MEDICAL INC.
  
    UNIT PUT AGREEMENT    
    

        THIS UNIT PUT AGREEMENT (this
"Agreement") is made and entered into as of September 16, 2008, by and among ProUroCare Medical Inc., a Nevada corporation (the
"Company"), and each of the investors listed on Schedule A hereto (each, a
"Purchaser" and collectively, the "Purchasers"). 

        WHEREAS, the Company wishes to sell and each of the Purchasers desires to purchase units consisting of unsecured, subordinated convertible
promissory notes and warrants to purchase shares of the Company's equity securities. 

        NOW, THEREFORE, the parties hereto hereby agree as follows: 

        1.    Authorization of the Securities.    The Company will have authorized, on or before the Closing (as defined
herein), the issuance and sale of Units consisting of unsecured, subordinated convertible promissory notes, substantially in the form attached hereto as  Exhibit A (the "Notes") and warrants to purchase shares of the Company's common stock, $0.00001
par value (the "Common Stock"), substantially in the form attached hereto as Exhibit B (the
"Warrants") at a price of $10,000 per unit (the "Units"). There is no minimum number of Units that must
be sold. The Company will sell up to a maximum of $750,000
of Units (the "Maximum Put Amount"). The Units, the Notes and the Warrants are hereinafter collectively referred to as the
"Securities." 

        2.    Sale and Purchase of the Securities.    Subject to the terms and conditions hereof, the Company will issue and
sell to each Purchaser, and each Purchaser will purchase from the Company (each such purchase and sale being referred to herein as a "Put"), up to the
total number of Units, the principal amount of Notes and the number of Warrants set forth opposite the name of each such Purchaser on Schedule A
attached hereto. The dollar amount paid by each Purchaser for the Units put to it by the Company under this Agreement shall be allocated as follows: 95% of such amount shall be the principal amount of
such Purchaser's Note and 5% of such amount shall be the purchase price for the Warrants. Each Purchaser shall receive a Warrant to purchase 2,000 shares of Common Stock for each $10,000 of Units
purchased under this Agreement. 

        3.    Closing Dates; Delivery and Payment.    

        3.1.    Closing Dates.    Each closing of a Put of Securities hereunder (a
"Closing") will be held at the offices of Dorsey & Whitney LLP on a date to be determined by and at the sole discretion of the Company;
provided that no Closing may be held more than six months after the date of execution of this Agreement.. Each time that the Company determines to hold a Closing, the Company shall give each of the
Purchasers notice of the planned Closing (a "Put Notice") at least five business days prior to the date of the planned Closing. Each Put Notice will
include the date of the planned Closing and the dollar amount of Units to be put to the Purchasers at the Closing. If the dollar amount of Units to be put at the Closing is equal to the Maximum Put
Amount, then each of the Purchasers shall be obligated to purchase at that Closing the number of Units set forth next to that Purchaser's name of  Schedule A attached hereto. If the dollar amount of
Units to be put at the Closing is less than the Maximum Put Amount, then each of the
Purchasers shall be obligated to purchase at that Closing a number of Units equal to the aggregate number of Units being put at that Closing multiplied by such Purchaser's Participation Percentage set
forth next to that Purchaser's name of Schedule A attached hereto; provided that any fractional units shall be rounded to the nearest whole Unit,
with any half Unit being rounded up to the next whole Unit. Notwithstanding the foregoing, the aggregate dollar amount of Units to be put to the Purchasers at any Closing shall not be less than 25% of
the Maximum Put Amount, unless the Units to be put at the Closing represent all of the remaining Units available to be put under this Agreement. 

        3.2.    Delivery and Payment.    At each Closing, the Company shall deliver to each Purchaser a Note registered in the
name of such Purchaser, representing the aggregate principal amount set 

forth
opposite the name of such Purchaser on Schedule A attached hereto (or portion thereof based on such Purchaser's Participation Percentage if
less than the Maximum Put Amount is being put at that Closing), together with a Warrant to purchase the number of shares of Common Stock set forth opposite the name of such Purchaser on  Schedule A
attached hereto (or portion thereof based on such Purchaser's Participation Percentage if less than the Maximum Put Amount is being
put at that Closing). At that Closing, each Purchaser shall pay to the Company by check or wire transfer an amount equal to the total purchase price for the Units set forth opposite the name of such
Purchaser on Schedule A attached hereto (or portion thereof based on such Purchaser's Participation Percentage if less than the Maximum Put
Amount is being put at that Closing). 

        4.    Definitions.    Unless the context otherwise requires, the terms defined in this Section 4 shall have the
meanings herein specified for all purposes of this Agreement. 

        "Code"
means the Internal Revenue Code of 1986, as amended, and the Treasury Regulations thereunder. 

        "Commission"
means the Securities and Exchange Commission. 

        "Exchange
Act" means the Securities Exchange Act of 1934, as amended from time to time. 

        "Material
Adverse Effect" means a material adverse effect upon the business, operations or condition (financial or otherwise) of the Company, or a material adverse effect that otherwise
renders the Company unable to perform its ongoing obligations. 

        "Person"
means any natural person, corporation, limited liability company, association, partnership (general or limited), joint venture, proprietorship, governmental agency, trust,
estate, association, custodian, nominee or any other individual or entity, whether acting in an individual, fiduciary, representative or other capacity. 

        "Private
Placement Memorandum" means the Company's private placement memorandum dated July 11, 2008. 

        "Public
Offering" means an underwritten public offering of equity securities of the Company. 

        "Securities
Act" means the Securities Act of 1933, as amended from time to time. 

        "SEC
Reports" means the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, the Company's Quarterly Reports on
Form 10-QSB for the quarters ended March 31, 2008 and June 30, 2008 and all of the Company's Current Reports on Form 8-K filed with the Commission
since January 1, 2008, through the date of the Closing. 

        5.    Representations and Warranties by the Company.    Except as disclosed on the Disclosure Schedule to this
Agreement (the "Disclosure Schedule") or in the SEC Reports, the Company represents and warrants to the Purchasers that: 

        5.1.    Organization and Standing.    Each of the Company and its subsidiary is a corporation duly organized, validly
existing and in good standing under the laws of its jurisdiction of incorporation and has the requisite corporate power and authority to own its properties and to carry on its business as now being
conducted and presently proposed to be conducted. The Company has no subsidiaries other than as set forth in the SEC Reports. Each of the Company and its subsidiary is duly qualified to do business as
a foreign corporation in all jurisdictions in which the failure to do so could reasonably be expected to result in a Material Adverse Effect. 

        5.2.    Notes and Warrants.    The Securities, when issued and paid for pursuant to the terms of this Agreement, will
be duly and validly authorized, issued and outstanding, fully paid, nonassessable and free and clear of all pledges, liens, encumbrances and restrictions, except as set forth in Section 6.2
hereof. The shares of Common Stock issuable upon conversion of the Notes (the "Conversion Shares") and upon exercise of the Warrants (the
"Warrant Shares"), when issued upon such conversion or exercise, will be duly and validly authorized, issued and outstanding, fully 

paid,
nonassessable and free and clear of all pledges, liens, encumbrances and restrictions, except as set forth in Section 6.2 hereof. 

        5.3.    Securities Laws.    Based in part upon the representations and warranties of the Purchasers contained in
Section 6.1 of this Agreement, no consent, authorization, approval, permit or order of or filing with any governmental or regulatory authority is required under current laws and regulations in
connection with the execution and delivery of this Agreement or the offer, issuance, sale or delivery of the Securities, other than the qualifications and filings under certain applicable state
securities laws, which
qualifications and filings have been or will be effected as a condition of such sales or conversions. The Company has not, directly or through an agent, offered the Securities or any similar
securities for sale to, or solicited any offers to acquire such securities from, Persons other than the Purchasers and other accredited investors. Under the circumstances contemplated hereby, the
offer, issuance, sale and delivery of the Securities will not under current laws and regulations require compliance with the prospectus delivery or registration requirements of the Securities Act. The
Conversion Shares and the Warrant Shares will be issued in compliance with all applicable federal and state securities laws. 

        5.4.    Corporate Acts and Proceedings.    The execution and delivery of this Agreement has been duly authorized by
all requisite corporate action on the part of the Company, its officers, directors and shareholders and this Agreement has been duly executed and delivered by an authorized officer of the Company.
This Agreement is a valid and binding obligation of the Company enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, moratorium,
reorganization or other similar laws affecting the enforcement of creditors' rights generally and as to limitations on the enforcement of the remedy of specific performance and other equitable
remedies. The requisite corporate action necessary to the authorization, creation, issuance, execution and delivery of the Securities has been taken by the Company, its officers, directors and
shareholders. 

        5.5.    Litigation.    There are no legal actions, suits, arbitrations or other legal, administrative or governmental
proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company, or any officer or director of the Company relating to their duties under such position in the
Company, or the Company's properties, assets or business, which could reasonably be expected to result in a Material Adverse Effect, or that questions the validity of this Agreement or the right of
the Company to enter into this Agreement, or to consummate the transactions contemplated hereby, and neither the Company nor any of its officers is aware of any facts which might result in or form the
basis for any such action, suit or other proceeding. The Company is not in default with respect to any judgment, order or decree of any court or any governmental agency or instrumentality. 

        5.6.    SEC Reports.    The SEC Reports constitute all of the periodic reports required to be filed by the Company
under the Exchange Act since January 1, 2008. The SEC Reports complied in all material respects with the Commission's requirements as of their respective filing dates, and the information
contained therein as of the respective dates thereof did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein in light of the circumstances under which they were made not misleading. 

        5.7.    Capital Stock.    As of August 19, 2008, the authorized capital stock of the Company consisted of
50,000,000 shares of Common Stock, of which 1,786,984 shares were issued and outstanding. As of August 19, 2008, the Company has reserved 300,000 shares of Common Stock for issuance pursuant to
awards granted under its 2002 Stock Plan and its 2004 Stock Option Plan, of which options to purchase 238,000 shares are currently outstanding. The Company has reserved 781,611 shares of Common Stock
for issuance pursuant to the exercise of outstanding warrants and 292,980 shares of Common Stock pursuant to the conversion of outstanding convertible securities. As of August 19, 2008, the
Company has also reserved as consideration to certain loan guarantors and individual lenders, 24,445 shares of common stock and up to 125,505 shares to be issued 

pursuant
to warrants. Except for such outstanding options, warrants and convertible securities as disclosed on Schedule 5.7 hereto, the issuance
of an aggregate of $1,757,500 of outstanding convertible promissory notes in the Company's 2007 and 2008 private placements and the issuance of an outstanding convertible promissory note in the amount
of $142,500 in connection with the conversion of a short-term loan from an investor, no person holds or is entitled to any outstanding subscriptions, warrants, options, calls, convertible
securities, commitments of sale or similar rights to purchase or otherwise acquire any shares of, or any security convertible into or exchangeable for, the capital stock of, or other ownership
interest in, the Company. 

        5.8.    No Conflict.    Neither the authorization, execution, delivery or performance of, or compliance with, this
Agreement nor the consummation of the transactions contemplated hereby will, with or without the giving of notice or passage of time, (a) result in any breach of, constitute a default under or
result in the imposition of any pledges, liens, encumbrances or restrictions upon any asset or property of the Company pursuant to any agreement or other instrument to which the Company is a party or
by which it or any of its properties is bound or affected or (b) violate its articles of incorporation or its bylaws. 

        5.9.    No Brokers or Finders.    No Person has, or will have, as a result of any acts or omission of the Company, any
rights, interest or valid claim against the Purchaser for any commission, fee or other compensation as a finder or broker in connection with the transactions contemplated by this Agreement. The
Company will indemnify and hold the Purchaser harmless against any and all liability with respect to any such commission, fee or other compensation which may be payable or determined to be payable by
the Purchaser in connection with the transactions contemplated by this Agreement. 

        6.    Representations and Warranties of the Purchasers; Restrictions on Transfer.    

        6.1.    Representations and Warranties of the Purchasers.    Each Purchaser represents and warrants that: 

        (a)    The
Purchaser is purchasing the Securities, the Conversion Shares and Warrant Shares for such Purchaser's own account and not with the view to, or for resale in
connection with, any distribution or public offering thereof. Such Purchaser has no current plan or intention to engage in a sale, exchange,
transfer, distribution, redemption, reduction in any way of such Purchaser's risk of ownership by short sale or otherwise, or other disposition, directly or indirectly of the Securities, Conversion
Shares or Warrant Shares. Such Purchaser is able to bear the economic risk of its investment and has the knowledge and experience in financial and business matters that it is capable of evaluating the
merits and risks (including tax considerations) of its investment, including the high degree of risk of loss of such Purchaser's entire investment herein. 

        (b)    The
Purchaser understands that none of the Securities, Conversion Shares or Warrant Shares has been registered under the Securities Act or any state securities laws by
reason of their contemplated issuance in transactions exempt from the registration requirements of the Securities Act pursuant to Section 4(2) thereof or Rule 505 or 506 promulgated
under the Securities Act and applicable state securities laws, and that the reliance of the Company and others upon these exemptions is predicated in part upon this representation by such Purchaser.
The Purchaser further understands that the Securities, Conversion Shares or Warrant Shares may not be offered, sold, transferred, pledged or hypothecated without (i) registration under the
Securities Act and any applicable state securities laws, or (ii) an exemption from the requirements of the Securities Act and applicable state securities laws. The Purchaser understands
(i) that the Units will not have any registration rights with respect to the Notes, Warrants, Conversion Shares or Warrant Shares, (ii) that an exemption from such registration is not
presently available pursuant to Rule 144 promulgated under the Securities Act by the Commission, and (iii) that in any event the Purchaser may not sell any securities acquired hereunder
pursuant to Rule 144 prior to the expiration of a six-month period (or such shorter period as the Commission may hereafter 

adopt)
after such Purchaser has acquired such securities. The Purchaser understands that any sales pursuant to Rule 144 can be made only in full compliance with the provisions of
Rule 144. 

        (c)    The
Purchaser has had an opportunity to consult with his, her or its own legal counsel in connection with this Agreement and the transactions contemplated by this
Agreement. The Purchaser has also had an opportunity to review the financial consequences of the purchase of the Securities with his, her or its financial advisor and/or tax advisor and is fully
familiar with the financial affairs of the Company. The Purchaser has received the Company's Private Placement Memorandum. The Purchaser has access to the SEC Reports, all of which are filed
electronically with the Commission. 

        (d)    The
Purchaser has not purchased the Securities as a result of any form of general solicitation or general advertising, including advertisements, articles, notices or
other communications published in any newspaper, magazine or similar media or broadcast over radio, or television, or any seminar or meeting whose attendees have been invited by general solicitation
or general advertising. 

        (e)    The
principal office or residence of such Purchaser is the address set forth on such Purchaser's signature page attached hereto. The Purchaser, by execution of this
Agreement, hereby represents that he, she or it qualifies as an "accredited investor" for purposes of Regulation D promulgated under the Securities Act. The Purchaser (i) is an investor
in securities of companies in the development stage and
acknowledges that it is able to fend for itself, and bear the loss of his, her or its entire investment in the Securities, the Conversion Shares and the Warrant Shares and (ii) has such
knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the investment to be made by it pursuant to this Agreement. If other than an
individual, the Purchaser also represents that it has not been organized solely for the purpose of acquiring the Securities. Such Purchaser has had access to all of the Company's material books and
records and the Company has made available to such Purchaser at a reasonable time prior to execution of this Agreement the opportunity to ask questions and receive answers concerning the terms and
conditions of the sale of securities contemplated by this Agreement and to obtain any additional information (which the Company possesses or can acquire without unreasonable effort or expense) as may
be necessary to verify the accuracy of information furnished to such Purchaser by the Company. 

        (f)    No
Person has or will have, as a result of any act or omission by such Purchaser, any right, interest or valid claim against the Company for any commission, fee or other
compensation as a finder or broker, or in any similar capacity, in connection with the transactions contemplated by this Agreement. Such Purchaser will indemnify and hold the Company harmless against
any and all liability with respect to any such commission, fee or other compensation which may be payable or determined to be payable in connection with the transactions contemplated by this
Agreement. 

        6.2.    Restrictions on Transfer.    

        (a)    In
addition to any legends required under state securities laws, each certificate representing the Notes or Warrants shall be endorsed with substantially the following
legend: 

"THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE PROVISIONS OF ANY APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES MAY
NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED." 

        Upon
the conversion or exercise of the Notes or Warrants, unless the Company receives an opinion of counsel reasonably satisfactory to the Company to the effect that a transfer of the
Conversion Shares or the Warrant Shares may be made without registration, or unless such Conversion Shares or Warrant Shares are being disposed of pursuant to a registration under the Securities Act,
substantially the same legend shall be endorsed on the certificate evidencing such Conversion Shares and Warrant Shares. 

        (b)    Any
legend endorsed on a certificate evidencing the Notes or Warrants pursuant to Section 6.2(a) hereof shall be removed, and the Company shall issue a
certificate without such legend to the holder of the Notes or Warrants, if the Notes or Warrants are being disposed of pursuant to a registration under the Securities Act or if such holder provides
the Company with an opinion of counsel reasonably satisfactory to the Company to the effect that a transfer of the Notes or Warrants may be made without registration. 

        7.    Conditions of Each Purchaser's Obligation at Closing.    The obligation of each Purchaser to purchase the
Securities at each Closing is subject to the fulfillment by the Company or waiver by such Purchaser prior to or on the date of the Closing of the conditions set forth in this Section 7. 

        7.1.    Representations and Warranties.    The representations and warranties of the Company under this Agreement
shall be true in all material respects as of the Closing, with the same effect as though made on and as of such date. 

        7.2.    Compliance with Agreements.    The Company shall have performed and complied in all respects with all
agreements or conditions required by this Agreement to be performed and complied with by it prior to or as of the Closing. 

        7.3.    Certificate of Officers.    The Company shall have delivered to the Purchasers or their respective counsel a
certificate, dated as of the Closing, executed by the President of the Company, certifying to the satisfaction of the conditions specified in Sections 7.1 and 7.2. 

        7.4.    Supporting Documents.    The Company shall have delivered to the Purchasers the following: 

        (a)   a
copy of resolutions of the Board of Directors of the Company authorizing and approving the sale, execution and delivery of the Securities, and authorizing and
approving the execution, delivery and performance of this Agreement, all such resolutions to be certified by an Officer of the Company; and 

        (b)   a
Certificate of Incumbency executed by an Officer of the Company certifying the names, titles and signatures of the officers authorized to execute this Agreement, the
Notes and Warrants, and further certifying that the articles of incorporation and bylaws of the Company, copies of which shall be attached as exhibits to such certificate, have been validly adopted
and have not been amended or modified. 

        7.5.    Qualification under State Securities Laws.    All registrations, qualifications, permits and approvals
required under applicable state securities laws for the lawful execution and delivery of this Agreement
and the offer, sale, issuance and delivery of the Securities to the Purchasers at the Closing shall have been obtained or will be obtained by the Company in compliance with such laws. 

        8.    Conditions of the Company's Obligations at Closing.    Unless otherwise waived by the Company in writing, the
obligations of the Company under this Agreement are subject to (i) the representations and warranties of each Purchaser contained in Section 6.1 being true and correct in all material
respects on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing and (ii) the Purchasers having performed and complied
in all respects with all agreements or conditions required by this Agreement to be performed and complied with by them prior to or as of the Closing. 

        9.    Covenants of the Company.    

        9.1.    Reservation of Shares.    The Company shall reserve, out of its authorized and unissued capital stock, an
adequate number of shares of Common Stock to enable the immediate issuance of such shares upon conversion of the Notes or exercise of the Warrants. If at any time the number of authorized but unissued
shares of capital stock shall not be sufficient to enable the conversion of the Notes or exercise of the Warrants, the Company will use its reasonable best efforts to take such corporate action as may
be necessary to increase its authorized but unissued shares of capital stock to such number of shares of capital stock as shall be sufficient for such purpose. 

        9.2.    Due Issuance.    All shares, when issued in accordance with the terms of the Notes and Warrants, shall be duly
authorized and issued, fully paid and nonassessable shares, and shall be free of all pledges, liens and encumbrances other than restrictions on transfer set forth in Section 6.2 hereof and the
applicable federal and state securities laws. 

        9.3    Public Information Requirements.    The Company agrees to meet the current public information requirements of
Rule 144 under the Securities Act until the earlier of (i) eighteen months from the date hereof or (ii) the date on which the Notes are no longer outstanding. 

        10.    Intentionally Omitted.    

        11.    Miscellaneous.    

        11.1.    Notices.    All notices, requests, consents and other communications required hereunder shall be in writing
and shall be personally delivered, sent by delivery service or mailed (in either case with 3-day delivery guaranteed), to the addresses listed below, or at such other address as the
Company or the Purchasers may specify by written notice: 

			
	 
	 	 

	To the Company:	 	With copies to:
	

ProUroCare Medical Inc.	
 	

Dorsey & Whitney LLP
	5500 Wayzata Boulevard	 	50 South Sixth Street
	Suite 310	 	Suite 1599
	Golden Valley, MN 55416	 	Minneapolis, Minnesota 55402
	Attention: Chief Executive Officer	 	Attention: Timothy S. Hearn, Esq.
	

To the Purchasers:	
 	

 
	

The addresses listed on Schedule A

attached hereto	
 	

 

Such
notices and other communications shall for all purposes of this Agreement be treated as being effective or having been given if delivered personally, or, if sent by mail or delivery service, when
received. 

        11.2.    Survival of Representations and Warranties.    All representations and warranties contained herein shall
survive the execution and delivery of this Agreement, any investigation at any time made by or on behalf of the Purchasers, and the sale and purchase of the Securities and payment therefor. All
statements contained in any certificate, instrument or other writing delivered by or on behalf of the Company pursuant hereto or in connection with or in contemplation of the transactions herein
contemplated shall constitute representations and warranties by the Company hereunder. 

        11.3.    Parties in Interest.    All the terms and provisions of this Agreement shall be binding upon and inure to the
benefit of and be enforceable by the respective successors and assigns of the parties hereto but shall inure to the benefit of and be enforceable by the holder or holders from time to time of any of
Securities only to the extent herein specifically provided. 

        11.4.    Assignability.    This Agreement may not be assigned by the Company or the Purchasers without the prior
written consent of the Company in the case of any Purchaser, or a majority of the Purchasers in the case of the Company. 

        11.5.    Modification; Waiver.    Any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the Purchasers obligated to purchase a
majority of the aggregate principal amount of the Notes to be issued pursuant to this Agreement if such consent is given prior to the first Closing hereunder, or the Company and the Purchasers holding
a majority of the outstanding aggregate principal amount of the Notes issued pursuant to this Agreement if such consent is given after the first Closing hereunder (the
"Majority Purchasers"). Any waiver or amendment effected in accordance with this Section shall be binding upon each party to this Agreement. By the
operation of this Section, each Purchaser acknowledges that the Majority Purchasers will have the right and power to diminish or eliminate all rights of such Purchaser under this Agreement. 

        11.6.    Severability.    If any provision contained herein is held to be invalid or unenforceable by a court of
competent jurisdiction, such provision will be severed herefrom and such invalidity or unenforceability will not affect any other provision of this Agreement, the balance of which will remain in and
have its intended full force and effect; provided, however, if such invalid or unenforceable provision may be modified so as to be valid and enforceable as a matter of law, such provision will be
deemed to have been modified so as to be valid and enforceable to the maximum extent permitted by law. 

        11.7.    Headings.    The headings of the sections of this Agreement have been inserted for convenience of reference
only and do not constitute a part of this Agreement. 

        11.8.    Choice of Law.    It is the intention of the parties that the internal laws of the State of Minnesota,
without regard to the body of law controlling conflicts of law, shall govern the validity of this Agreement, the construction of its terms and the interpretation of the rights and duties of the
parties. 

        11.9.    Counterparts.    This Agreement may be executed concurrently in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. 

        IN WITNESS WHEREOF, the Company has caused this Unit Put Agreement to be duly executed and delivered by its proper and duly authorized
representative and each of the Purchasers has caused this Unit Put Agreement to be executed by signing in counterpart the acceptance form attached to this Agreement. 

					
	 
	 	 
	 	 

	 	 	PROUROCARE MEDICAL INC.
	

 	
 	

By:	
 	

/s/ RICHARD C. CARLSON

	 	 	Name:	 	Richard C. Carlson

	 	 	Title:	 	CEO

[SIGNATURE PAGE TO UNIT PUT AGREEMENT]  

QuickLinks

Exhibit 10.43

PROUROCARE MEDICAL INC. UNIT PUT AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]